CytoSeek Appoints New Chairperson, Strengthens Scientific Advisory Board

BRISTOL, England. CytoSeek Ltd, a discovery-stage biotech company developing the next generation of Artificial Membrane-Binding Proteins (AMBPs) to treat cancer, is excited to announce the appointment of Damian Marron as Chairperson and a Director of the Company, and Professor Karl Peggs as a member of its Scientific Advisory Board (SAB).

CytoSeek is a spin-out from the University of Bristol, based on the research of Professor Adam Perriman (Professor of Bioengineering, School of Cellular and Molecular Medicine), who developed CytoSeek’s pioneering AMBP technology. The company’s genetic-modification-free technology enables the rapid addition of new functionalities to cell therapies that radically improve their performance. CytoSeek’s primary goal is to develop efficacious cell therapies for the treatment of cancers caused by solid tumours.

Damian is an accomplished life sciences executive with a successful track record of leadership in public and private biotechnology companies. In former CEO roles he has successfully exited several companies, including those in the cell therapy and immuno-oncology field and currently holds Board positions in a number of companies in the UK and Europe at clinical and pre-clinical stage. His exit experience spans both IPO and M&A transactions complementing his experience in earlier-stage biotech fundraising and in executing partnerships with top-tier pharmaceutical companies.

“CytoSeek’s technology has the potential to enable a major step forward for cell therapies, helping unlock their potential to treat cancer with a flexible and easy to use technology . I am impressed withwhat the team has achieved in a short period of time and looking forward to contributing to the company’s future success.” said Damian.

“I am delighted that we have secured someone of Damian’s calibre to take the company onwards in next phase of its development. am really pleased with the progress we have made over the past the2 years and look forward to remaining as an active board member supporting Damian and themanagement team.” said Keith MacDonald, outgoing Chair of CytoSeek who will remain on theBoard.

In addition to expanding its Board of directors, CytoSeek has also augmented its SAB with the appointment of Professor Karl Peggs. Karl is a pioneer in the field of adoptive cell therapies for cancer immunotherapy and is currently a Professor of Transplant Science and CancerImmunotherapy at UCL Cancer Institute, Scientific Director of the NIHR Blood and TransplantResearch Unit for Stem Cells and Immunotherapies, and Clinical and Scientific Director of the Sir Naim Dangoor Centre for Cellular Immunotherapy at UCLH where he has established the clinical translational side of the academic CAR T cell programme.

“I am excited to be working with Damian and Karl to help deliver on the next phase of CytoSeek’s growth. Following a busy 2020 we are in a strong position as we approach our next fundraise having strengthened our team, expanded our presence outside the University of Bristol and secured anInnovate grant.” said Carolyn Porter, CEO of CytoSeek.

By | 2020-11-06T10:58:40+00:00 November 6th, 2020|Press Releases|